Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Testosterone
Drug ID BADD_D02170
Description Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.[A186943]
Indications and Usage Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995]
Marketing Status approved; investigational
ATC Code G03BA03
DrugBank ID DB00624
KEGG ID D00075
MeSH ID D013739
PubChem ID 6013
TTD Drug ID D06XMU
NDC Product Code 0832-1120; 65089-0050; 43598-304; 49884-418; 63629-8455; 63629-9310; 0591-2925; 38779-2936; 43647-568; 43742-1436; 73774-014; 76003-1083; 43742-1242; 0245-0871; 62332-552; 70700-112; 76420-685; 76420-687; 76420-699; 24979-130; 45802-610; 0051-8462; 64380-151; 68180-943; 69097-363; 0591-2363; 0603-7831; 0009-5020; 44132-006; 49452-7658; 64025-0010; 45802-281; 0245-0872; 0023-5992; 63629-2125; 64380-152; 66887-001; 0591-2114; 0591-2924; 0591-2926; 0591-3216; 0832-1121; 51927-0267; 70492-002; 76420-684; 0009-0074; 12875-8248; 22552-0009; 49452-7652; 60592-721; 60870-0251; 16714-967; 17139-562; 63629-2124; 68180-941; 44132-008; 48087-0113; 51552-0029; 42667-5511; 63481-183; 63629-2352; 69238-1013; 0591-3217; 0591-3524; 38779-0163; 38779-2598; 82393-113; 24979-078; 45802-366; 66887-004; 51552-0564; 62991-2150; 76420-686; 16714-969; 45802-754; 49884-510; 62332-488; 69339-158; 0591-2921; 49452-7657; 16714-968; 0023-5990
UNII 3XMK78S47O
Synonyms Testosterone | 17-beta-Hydroxy-4-Androsten-3-one | 17 beta Hydroxy 4 Androsten 3 one | Androtop | Histerone | Sterotate | Sustanon | Androderm | Testoderm | Testolin | Testopel | Testosterone Sulfate | AndroGel | 8-Isotestosterone | 8 Isotestosterone | 17-beta-Hydroxy-8 alpha-4-Androsten-3-one | 17 beta Hydroxy 8 alpha 4 Androsten 3 one | Andropatch | Testim
Chemical Information
Molecular Formula C19H28O2
CAS Registry Number 58-22-0
SMILES CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sensory loss17.02.07.0070.000200%-
Serum sickness10.01.03.004; 12.02.08.004--
Shock24.06.02.002---
Sinusitis11.01.13.005; 22.07.03.007--
Skin disorder23.03.03.007---
Skin hypertrophy23.01.04.0020.000200%-
Skin irritation23.03.04.0090.002099%-
Skin odour abnormal23.03.03.0120.000772%
Sleep apnoea syndrome17.15.05.001; 19.02.05.002; 22.02.01.0130.000545%
Sleep disorder19.02.04.001---
Snoring22.12.03.025---
Spermatocele16.36.02.001; 21.13.02.002---
Stomatitis07.05.06.005--
Strangury20.02.02.017---
Suicidal ideation19.12.01.003--
Surgery25.01.02.003---
Swelling08.01.03.015---
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Systemic lupus erythematosus10.04.03.004; 15.06.02.003; 23.03.02.006---
Tachycardia02.03.02.007---
Tenderness08.01.08.005---
Tension19.06.02.0050.001999%-
Testicular atrophy05.05.02.004; 21.13.01.0010.001372%-
Testicular disorder21.13.01.0020.000309%
Testicular pain21.13.01.0050.000818%
Therapeutic response decreased08.06.01.016---
Throat tightness19.01.02.005; 22.12.03.031---
Thrombocytopenia01.08.01.002---
Thrombophlebitis24.01.02.0010.000473%-
Thrombosis24.01.01.0060.022629%-
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 19 Pages